Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Atezolizumab vs Sorafenib in advanced hepatocellular carcinoma
NCT03755791Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Exelixis, Inc.. Started Jun 2018; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03755791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755791.